Exelixis is focused on maximizing the opportunity for its two internally discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer.
Discovered by Exelixis, and the focus of our development and commercialization efforts, cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.
Cobimetinib is a reversible inhibitor of MEK, also known as mitogen-activated protein kinase. Cobimetinib is being developed by Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis.
XL888 was discovered by Exelixis and is wholly owned by the company. It is a highly potent and orally bioavailable ATP-competitive inhibitor of HSP90, that, in preclinical studies has been shown to inhibit the proliferation of a broad panel of human tumor cell lines, and to induce marked degradation of HSP90 client proteins, including BRAF, MET, and HER2.